Abstract:Abstract Introduction/Objective Plasma is generally transfused to replenish coagulation factors to stop bleeding. It is processed as “Fresh Frozen Plasma” (FFP), wherein units are frozen within 8 hours of collection from the donor for storage, and thawed in a 30-37 C water bath before usage. The Association for the Advancement of Blood & Biotherapies (AABB) recommends a dose of 15 ml/kg plasma in adults, and one unit of FFP is 200-250 ml in volume. Plasma units are recommended to be transfused within 6 hours at a rate of 2-3 ml/kg/hour. At Danbury Hospital, Connecticut, there has been a tendency of clinicians to order only one unit of FFP, however, the recommended dose is at least two units. The exact incidence of one unit of FFP usage was not well known before the initiation of this study. This retrospective study aimed to focus on the incidence of the administration of single unit FFP and estimate the effect of education to clinicians regarding the recommended dosage of FFP. Methods/Case Report Inappropriate quantity was defined as the administration of only 1 FFP dose given more than 6 hours from any other FFP dose(s), either before or after. The study included all patient cases with orders of fresh frozen plasma at Danbury Hospital, Connecticut, from Dec 1, 2020 to April 30, 2022. Patients under 18 years of age were excluded from the study. Education was provided continuously during the time period through telephone calls. Data was gathered both from blood bank records and the electronic medical record system. Trend analysis was performed on the incidence of recommended versus inappropriate dosage over the time period. Results (if a Case Study enter NA) 94 patients were given FFP at Danbury Hospital, Connecticut, from Dec 1, 2020 to April 30, 2022. There were 49 instances of an inappropriate dose of FFP given more than 6 hours from any other FFP dose(s), resulting in a rate of 0.52 instances of inappropriate doses per patient. The rate of inappropriate doses of FFP per patient was 0.53 during the first half of the time period studied, and 0.52 during the second half. There was no significant trend in the rate of FFP doses per patient during the time period (P value: 0.9998). Conclusion We did not find a statistically significant change in the fresh frozen plasma (FFP) orders at our institution despite the education of clinicians by telephone contact. A robust systematic education of clinicians with digital order entry forms to actively motivate clinicians for at least two units may be required to result in a significant change in clinician practice.

The Safety of Fresh Frozen Plasma for the Treatment of Hereditary Angioedema

Fresh Frozen Plasma Transfusion Induced Anaphylactic Shock: A Case Report

Advent of oral medications for the treatment of hereditary angioedema

Prophylaxis in hereditary angioedema: a United Kingdom Delphi consensus

EFFECT OF EDUCATION FOR THE CLINICAL USAGE OF FRESH FROZEN PLASMA

Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS

Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry

Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study

An expert panel's review on patients with hereditary angioedema switching from attenuated androgens to oral prophylactic therapy

Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group

Long-term Prophylaxis with Androgens in the Management of Hereditary Angioedema (HAE) in Emerging Countries

Audit of fresh frozen plasma usage, prospective study: a report from department of immunohematology and transfusion medicine, government medical college Jammu, Jammu and Kashmir, India

Phase 4 Safety and Efficacy Study of Antihemophilic Factor (recombinant) in Previously Treated Chinese Patients with Severe/Moderately Severe Hemophilia A.

An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema

Freeze-dried plasma in major haemorrhage: a systematic review

The Future of Therapeutic Options for Hereditary Angioedema

Hereditary angioedema, emergency management of attacks by a call center

Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study

Long-Term Safety Analysis of a Fibrinogen Concentrate (RiaSTAP®/Haemocomplettan® P)

Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema

Donor‐type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant